Back to Journals » Oncolytic Virotherapy » Volume 4

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy

Authors Nakashima H, Nguyen T, Chiocca EA

Received 30 August 2015

Accepted for publication 15 October 2015

Published 20 November 2015 Volume 2015:4 Pages 183—191

DOI https://doi.org/10.2147/OV.S66081

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ahmed Majeed Al-Shammari

Peer reviewer comments 2

Editor who approved publication: Dr Faris Farassati


Hiroshi Nakashima, Tran Nguyen, Ennio Antonio Chiocca

Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA

Abstract: Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi.

Keywords: epigenetics, glioma, oncolytic virus, HDAC inhibitor, HSV-1, cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]